ARTICLE | Clinical News

NIH begins second trial of NewLink's Ebola vaccine

October 23, 2014 2:50 AM UTC

NewLink Genetics Corp. (NASDAQ:NLNK) gained $4.01 (12%) to $38.51 on Wednesday after NIH's National Institute of Allergy and Infectious Diseases (NIAID) said it had begun the second Phase I trial of its investigational Ebola vaccine VSV-EBOV (BPSC1001).

The trial's 39 healthy adults will receive two injections of the same dose of the vaccine, 28 days apart. Initial safety and immune response data are expected by YE14, and participants will be re-evaluated 11 times over one year. ...